Boston Scientific Corporation today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Express2(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent System. The TAXUS Express Atom Stent is a highly deliverable drug-eluting stent (DES) specifically designed for treating small coronary vessels.
The details can be read here.
No comments:
Post a Comment